Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn

2026-03-10 - 11:13

UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds Business live – latest updates The pipeline of new drugs to fight superbugs remains “worryingly thin” and has shrunk by 35% in the last five years, experts have warned, predicting the annual number of deaths linked to drug-resistant infections globally will double to 8 million by 2050. The number of projects from large pharma companies has shrunk by 35% over the past five years, from 92 to 60 medicines in development, according to a report from the Access to Medicine Foundation (AMF), a Netherlands-based non-profit group, and the Wellcome Trust. Continue reading...